Navigation Links
Synthetic Biologics to Present at the 7th Annual OneMedForum San Francisco 2014 Conference
Date:1/8/2014

ROCKVILLE, Md., Jan. 8, 2014 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of product candidates focused on the prevention and treatment of serious infectious and other diseases, announced today that Jeffrey Riley, CEO, is scheduled to present at the 7th Annual OneMedForum San Francisco 2014 conference next week in San Francisco, as follows:

Date: Tuesday, January 14, 2014
Time: 11:30 a.m. (PT)/2:30 p.m. (ET)
Location: The Westin San Francisco Market Street Hotel

A live webcast of Synthetic Biologics' presentation can be accessed by logging onto the internet at http://onemedplace.com/forum/webcast/. After the presentation, a replay will be archived and accessible for 30 days at the same website.

(Logo: http://photos.prnewswire.com/prnh/20130522/MM19465LOGO)

About Synthetic Biologics, Inc.

Synthetic Biologics, Inc. (NYSE MKT: SYN) is a biotechnology company focused on the development of product candidates for serious infectious and other diseases. Synthetic Biologics is developing oral treatments targeting archaea, a non-bacterial intestinal form of life increasingly associated with chronic diseases such as irritable bowel syndrome (IBS), obesity and type 2 diabetes, an oral biologic to protect the gastrointestinal microflora from the effects of IV antibiotics for the prevention of C. diff infection, a series of monoclonal antibodies (mAbs) for the treatment of Pertussis and Acinetobacter infections, and a biologic targeted at the prevention and treatment of IBS. In addition, the Company is developing an oral estriol drug candidate for the treatment of relapsing-remitting multiple sclerosis (MS) and cognitive dysfunction in MS (with results of an ongoing 164 subject, 15 center, two-year, double blind, placebo controlled, Phase II relapsing-remitting MS clinical trial expected to be announced during the first half of 2014). For more information, please visit Synthetic Biologics' website at www.syntheticbiologics.com.


'/>"/>
SOURCE Synthetic Biologics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Green Dot Develops Compostable Synthetic Leather Made with its Terratek® Flex Bioplastic
2. Synthetic Biologics Announces Exercise of Underwriters Over-Allotment Option
3. Synthetic Biologics Announces Proposed Public Offering of Common Stock
4. Global Geosynthetics Market 2012-2016
5. Process holds promise for production of synthetic gasoline
6. Startup to Strengthen Synthetic Biology and Regenerative Medicine Industries with Cutting Edge Cell Products
7. Advancements in High-Speed DNA Synthesis to Drive Growth in the Global Synthetic Biology Market, According to New Report by Global Industry Analysts, Inc.
8. Synthetic Biologics SYN-004 for the Prevention of C. difficile Infections Named a "Top Project to Watch" by Elsevier Business Intelligence
9. Synthetic Biologics Reports Third Quarter 2013 Financial Results and Operational Update
10. China Synthetic Resin Industry Report, 2013-2016
11. Synthetic Biologics to Report Third Quarter 2013 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... (PRWEB) , ... April 20, 2017 , ... ... to the scientific and clinical research community’s growing body of knowledge during its ... in the Gracie Theatre and the adjacent Darling Atrium. During the event, undergraduates, ...
(Date:4/20/2017)... , ... April 20, 2017 , ... Parallel6™ , ... trials worldwide, announced today that they were named one of the 2017 Top ... the latest developments in the pharmaceutical industry. , “We take pride in honoring Parallel6 ...
(Date:4/20/2017)... , April 20, 2017 For ... focuses on novel drug development and clinical research aimed at ... Biostage Inc. (NASDAQ: BSTG), Keryx Biopharmaceuticals Inc. (NASDAQ: KERX), Kite ... ZIOP ). You can access our complimentary research reports ... ...
(Date:4/19/2017)... ... 2017 , ... Optofluidics today announced that it's changing its ... changed focus to making analytical tools for biopharmaceutical quality control. “We are excited ... Robert Hart. Founders Bernardo Cordovez, Robert Hart and David Erickson have steered the ...
Breaking Biology Technology:
(Date:4/3/2017)... April 3, 2017  Data captured by ... platform, detected a statistically significant association between ... to treatment and objective response of cancer ... to predict whether cancer patients will respond ... as well as to improve both pre-infusion potency ...
(Date:3/28/2017)... March 28, 2017 The report ... (Camera, Monitors, Servers, Storage Devices), Software (Video Analytics, VMS), ... - Global Forecast to 2022", published by MarketsandMarkets, the ... and is projected to reach USD 75.64 Billion by ... 2022. The base year considered for the study is ...
(Date:3/23/2017)... Mar. 23, 2017 Research and Markets has ... Analysis & Trends - Industry Forecast to 2025" report to ... ... a CAGR of around 8.8% over the next decade to reach ... analyzes the market estimates and forecasts for all the given segments ...
Breaking Biology News(10 mins):